G Passot1, N Bakrin1, A S Roux2, D Vaudoyer3, F-N Gilly1, O Glehen4, E Cotte1. 1. Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; Université Lyon 1, EMR 37-38, Lyon, France. 2. Hospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Unité de Recherche Clinique, Lyon, France. 3. Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France. 4. Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; Université Lyon 1, EMR 37-38, Lyon, France. Electronic address: olivier.glehen@chu-lyon.fr.
Abstract
INTRODUCTION: Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) have demonstrated promising results in the treatment of peritoneal carcinomatosis (PC). The purpose of this study was to assess the impact of this combined procedure on quality of life (QoL). MATERIALS AND METHODS: A prospective single centre study of 216 consecutive patients treated with CRS and HIPEC was conducted using the Gastro-Intestinal Quality of Life Index questionnaire (GIQLI), completed preoperatively and at 1, 3, 6 and 12 months. RESULTS: Questionnaire compliance was 81%, 90%, 89%, 89% and 74% at baseline, 1, 3, 6 and 12 months respectively. QoL was significantly decreased up to 6 months and returned to baseline at 12 months. In multivariate analysis, factors decreasing QoL were origin of PC at 3 months, presence of stoma at 6 months and length of surgery over 270 min and disease recurrence at 12 months. CONCLUSIONS: Despite morbidity associated with CRS and HIPEC, QoL returned to baseline at one year after surgery. This treatment strategy should be considered for the treatment of peritoneal carcinomatosis.
INTRODUCTION: Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) have demonstrated promising results in the treatment of peritoneal carcinomatosis (PC). The purpose of this study was to assess the impact of this combined procedure on quality of life (QoL). MATERIALS AND METHODS: A prospective single centre study of 216 consecutive patients treated with CRS and HIPEC was conducted using the Gastro-Intestinal Quality of Life Index questionnaire (GIQLI), completed preoperatively and at 1, 3, 6 and 12 months. RESULTS: Questionnaire compliance was 81%, 90%, 89%, 89% and 74% at baseline, 1, 3, 6 and 12 months respectively. QoL was significantly decreased up to 6 months and returned to baseline at 12 months. In multivariate analysis, factors decreasing QoL were origin of PC at 3 months, presence of stoma at 6 months and length of surgery over 270 min and disease recurrence at 12 months. CONCLUSIONS: Despite morbidity associated with CRS and HIPEC, QoL returned to baseline at one year after surgery. This treatment strategy should be considered for the treatment of peritoneal carcinomatosis.
Authors: Katharine E Duckworth; Richard P McQuellon; Gregory B Russell; Kathleen C Perry; Chandylen Nightingale; Perry Shen; Konstantinos I Votanopoulos; Bonny Morris; Edward A Levine Journal: J Am Coll Surg Date: 2020-01-31 Impact factor: 6.113
Authors: Anna P Lietz; Davis T Weaver; Alexander Melamed; Jose Alejandro Rauh-Hain; Jason D Wright; Alexi A Wright; Amy B Knudsen; Pari V Pandharipande Journal: PLoS One Date: 2019-09-20 Impact factor: 3.240
Authors: R Mirnezami; A M Mehta; K Chandrakumaran; T Cecil; B J Moran; N Carr; V J Verwaal; F Mohamed; A H Mirnezami Journal: Br J Cancer Date: 2014-09-16 Impact factor: 7.640
Authors: Maleen Leimkühler; Judith E K R Hentzen; Patrick H J Hemmer; Lukas B Been; Robert J van Ginkel; Schelto Kruijff; Barbara L van Leeuwen; Geertruida H de Bock Journal: Ann Surg Oncol Date: 2020-04-26 Impact factor: 5.344